Agenus (AGEN) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Agenus (NASDAQ:AGEN) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.12), MarketWatch Earnings reports.

Shares of NASDAQ AGEN opened at $2.99 on Friday. The company has a market cap of $336.00 million, a PE ratio of -2.43 and a beta of 2.09. Agenus has a 12-month low of $1.54 and a 12-month high of $6.02.

Several equities analysts have recently issued reports on AGEN shares. Zacks Investment Research downgraded Agenus from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. BidaskClub upgraded Agenus from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. Finally, ValuEngine upgraded Agenus from a “hold” rating to a “buy” rating in a research report on Thursday, January 17th.



Several hedge funds and other institutional investors have recently modified their holdings of AGEN. Northern Trust Corp increased its position in Agenus by 4.3% during the second quarter. Northern Trust Corp now owns 1,005,499 shares of the biotechnology company’s stock worth $2,282,000 after buying an additional 41,300 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Agenus by 26.7% during the third quarter. Wells Fargo & Company MN now owns 941,284 shares of the biotechnology company’s stock worth $2,015,000 after purchasing an additional 198,247 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Agenus by 3.1% during the third quarter. BlackRock Inc. now owns 5,896,521 shares of the biotechnology company’s stock worth $12,619,000 after purchasing an additional 178,555 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Agenus during the third quarter worth $105,000. Finally, Jefferies Group LLC boosted its holdings in shares of Agenus by 171.2% during the third quarter. Jefferies Group LLC now owns 166,523 shares of the biotechnology company’s stock worth $356,000 after purchasing an additional 105,123 shares during the last quarter. Institutional investors and hedge funds own 31.77% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Agenus (AGEN) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS” was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://dakotafinancialnews.com/2019/03/15/agenus-agen-posts-quarterly-earnings-results-misses-estimates-by-0-12-eps.html.

About Agenus

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Further Reading: Beta

Earnings History for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.